Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(12)
•••
Comment by MyKnighton Jun 27, 2019 11:27am
65 Views
Post# 29869855

RE:RE:RE:RE:RE:RE:RE:RE:Selling

RE:RE:RE:RE:RE:RE:RE:RE:SellingI didn't expect this company to bring money for another year or 2....

Now they will be bringing money this year, this is ahead of time, and expect that GVHD will be fast track ... So we could see money coming from GVHD in less then a year from now...

This is better then expected....

And 3.5 Millions , so we can grow our own CBD is great news, yes they're will be charge to produce, but when you produce CBD, you also get money coming in...we will produce what they need for the medical center at the lowest price available...

I've said it before if this company is under 500 Millions market cap is a steal, so if he plan(Rob) to run with royalties and partners this would bring way more money....

And for Apharia, Kaly didn't want to do business with them in Feb/2018, that's still true today... they will do better on their own...

The futur look incredible, if Rob play it right.

And yes don't forget what they found lately KAL-1816 ... $$$$
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities